Ovid Therapeutics Inc — 貸借対照表 (NASDAQ:OVID) | MetaTrader

チャート全体を表示

Financials

概要明細書統計

総資産 75.93 M194.54 M155.27 M144.03 M92.17 M150.93 M 負債合計 32.29 M14.8 M22.99 M56.23 M23.94 M20.27 M 純資産合計 43.63 M179.75 M132.27 M87.8 M68.23 M130.66 M 負債および純資産合計 75.93 M194.54 M155.27 M144.03 M92.17 M150.93 M 有利子負債合計 —————— 純負債 ——————

ニュース

Ovid Therapeutics Inc. (OVID) Discusses KCC2 Deep Dive and Pipeline Advances in CNS Disorders Transcript

3 Best Stocks to Buy Today, 4/7/2026, According to Top Analysts - TipRanks.com

Ovid Therapeutics: Seizing The Moment With Phase 2 Ready Assets And PIPE Funding

Ovid Therapeutics Inc. 2025 Q4 - Results - Earnings Call Presentation (NASDAQ:OVID) 2026-03-19

Ovid Therapeutics (OVID) Q4 Earnings and Revenues Surpass Estimates

Niagen Bioscience (NAGE) Tops Q4 Earnings and Revenue Estimates

PTC Therapeutics (PTCT) Reports Q4 Loss, Misses Revenue Estimates

Ovid Therapeutics: Bullish Post-PIPE With Two Differentiated CNS Moonshots

Ovid’s KCC2 activator shows promising safety in early trial

Ovid Therapeutics社の株主、授権株式数の増加と関連提案を承認

Ovid Therapeutics shareholders approve increase in authorized shares and related proposals

ロス/MKMがオービッド・セラピューティクスの株式をてんかん薬でBuy評価で開始